Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer Disease (AD).
Epistemonikos ID: 6ebdb3ce053cba95ab9483cb64f9e41000c3b235
First added on: May 04, 2024